HK1212245A1 - Molecular marker for cancer stem cell - Google Patents
Molecular marker for cancer stem cellInfo
- Publication number
- HK1212245A1 HK1212245A1 HK16100348.1A HK16100348A HK1212245A1 HK 1212245 A1 HK1212245 A1 HK 1212245A1 HK 16100348 A HK16100348 A HK 16100348A HK 1212245 A1 HK1212245 A1 HK 1212245A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- stem cell
- cancer stem
- molecular marker
- marker
- molecular
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003147 molecular marker Substances 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008275539 | 2008-10-27 | ||
JP2009068656 | 2009-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1212245A1 true HK1212245A1 (en) | 2016-06-10 |
Family
ID=42128561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16100348.1A HK1212245A1 (en) | 2008-10-27 | 2016-01-13 | Molecular marker for cancer stem cell |
Country Status (7)
Country | Link |
---|---|
US (4) | US8541544B2 (fr) |
EP (2) | EP3118326B1 (fr) |
JP (2) | JP5960946B2 (fr) |
CN (2) | CN104971341B (fr) |
ES (2) | ES2805553T3 (fr) |
HK (1) | HK1212245A1 (fr) |
WO (1) | WO2010050190A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010050190A1 (fr) | 2008-10-27 | 2010-05-06 | 北海道公立大学法人札幌医科大学 | Marqueur moléculaire de cellule souche cancéreuse |
JPWO2010107116A1 (ja) * | 2009-03-19 | 2012-09-20 | 独立行政法人科学技術振興機構 | Sox2由来のhla−a24結合性癌抗原ペプチド |
US8993604B2 (en) * | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
JPWO2015005479A1 (ja) * | 2013-07-12 | 2017-03-02 | 大日本住友製薬株式会社 | 腫瘍抗原ペプチド |
JP6486368B2 (ja) | 2013-09-06 | 2019-03-20 | アカデミア シニカAcademia Sinica | 改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化 |
JPWO2015050259A1 (ja) * | 2013-10-03 | 2017-03-09 | 大日本住友製薬株式会社 | 腫瘍抗原ペプチド |
KR20240096599A (ko) | 2014-05-27 | 2024-06-26 | 아카데미아 시니카 | 항-cd20 글리코항체 및 이의 용도 |
CA2950423A1 (fr) | 2014-05-27 | 2015-12-03 | Academia Sinica | Compositions et procedes concernant des glycoformes universelles pour une efficacite d'anticorps amelioree |
CN106661099A (zh) | 2014-05-27 | 2017-05-10 | 中央研究院 | 抗her2醣抗体及其用途 |
WO2015184001A1 (fr) | 2014-05-28 | 2015-12-03 | Academia Sinica | Glycoanticorps anti-thf-alpha et leurs utilisations |
SG10201901157QA (en) * | 2014-08-12 | 2019-03-28 | Gillies Mcindoe Res Institute | Cancer diagnosis and therapy |
KR20170095284A (ko) * | 2014-12-09 | 2017-08-22 | 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 | 종양 항원 펩티드 |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
CN107430127B (zh) * | 2015-01-24 | 2020-08-28 | 中央研究院 | 癌症标记及其使用方法 |
CA3034057A1 (fr) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Anticorps, fragments de liaison, et procedes d'utilisation |
WO2019143934A1 (fr) * | 2018-01-19 | 2019-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activité anticancéreuse de scbg3a2 et lps |
EP3530282A1 (fr) * | 2018-02-27 | 2019-08-28 | Diaccurate | Procédés thérapeutiques |
JPWO2020071554A1 (ja) * | 2018-10-05 | 2021-09-09 | 北海道公立大学法人 札幌医科大学 | がん幹細胞特異的抗体 |
CN110616185A (zh) * | 2019-09-25 | 2019-12-27 | 华东理工大学青岛创新研究院 | 一种多细胞肿瘤球及其高通量制备方法 |
AU2022351990A1 (en) * | 2021-09-27 | 2024-05-16 | The Florey Institute Of Neuroscience And Mental Health | Compositions and methods for the treatment of pcdh19 related disorders |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001233114A1 (en) * | 2000-02-04 | 2001-08-14 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
WO2004005883A2 (fr) * | 2002-07-02 | 2004-01-15 | The Johns Hopkins University | Marqueurs endotheliaux tumoraux secretes et cytoplasmiques |
AU2001286541A1 (en) * | 2000-08-17 | 2002-02-25 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer |
AU2002318112B2 (en) * | 2001-04-10 | 2007-12-06 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
AU2006273892A1 (en) * | 2005-07-26 | 2007-02-01 | Procure Therapeutics Limited | Prostate stem cell markers |
EP1961065A4 (fr) * | 2005-10-31 | 2009-11-11 | Oncomed Pharm Inc | Compositions et procedes pour diagnostiquer et traiter un cancer |
US7358231B1 (en) * | 2005-12-01 | 2008-04-15 | Applera Corporation | Pancreatic cancer secreted targets and uses thereof |
WO2007132883A1 (fr) | 2006-05-17 | 2007-11-22 | Yokohama City University | Procédé et trousse permettant d'identifier le cancer hépatique, de déterminer le stade de la maladie ou d'estimer le pronostic |
AU2008207945A1 (en) * | 2007-01-22 | 2008-07-31 | Macrogenics West, Inc. | Human cancer stem cells |
EP1980254A1 (fr) * | 2007-04-13 | 2008-10-15 | Rijksuniversiteit te Groningen | Moyens et procédé de annihilation d'agrégation de protéine |
WO2009036246A2 (fr) * | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogènes qui induisent des lymphocytes t cytotoxiques et leur utilisation dans la prévention, le traitement et le diagnostic du cancer |
WO2010050190A1 (fr) | 2008-10-27 | 2010-05-06 | 北海道公立大学法人札幌医科大学 | Marqueur moléculaire de cellule souche cancéreuse |
-
2009
- 2009-10-27 WO PCT/JP2009/005676 patent/WO2010050190A1/fr active Application Filing
- 2009-10-27 JP JP2010535664A patent/JP5960946B2/ja active Active
- 2009-10-27 CN CN201510185775.5A patent/CN104971341B/zh active Active
- 2009-10-27 ES ES16164792T patent/ES2805553T3/es active Active
- 2009-10-27 EP EP16164792.0A patent/EP3118326B1/fr active Active
- 2009-10-27 EP EP09823303.4A patent/EP2361988B1/fr active Active
- 2009-10-27 ES ES09823303.4T patent/ES2582208T3/es active Active
- 2009-10-27 US US13/126,039 patent/US8541544B2/en active Active
- 2009-10-27 CN CN200980142673.8A patent/CN102203290B/zh active Active
-
2013
- 2013-08-15 US US13/967,410 patent/US9399760B2/en active Active
-
2015
- 2015-11-25 JP JP2015230130A patent/JP6276742B2/ja active Active
-
2016
- 2016-01-13 HK HK16100348.1A patent/HK1212245A1/xx unknown
- 2016-05-24 US US15/162,833 patent/US10080776B2/en active Active
-
2018
- 2018-08-23 US US16/110,001 patent/US11382952B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20140044686A1 (en) | 2014-02-13 |
US10080776B2 (en) | 2018-09-25 |
US20110262358A1 (en) | 2011-10-27 |
EP2361988B1 (fr) | 2016-04-13 |
CN104971341A (zh) | 2015-10-14 |
US20190054141A1 (en) | 2019-02-21 |
US9399760B2 (en) | 2016-07-26 |
JP6276742B2 (ja) | 2018-02-07 |
EP2361988A9 (fr) | 2012-02-22 |
US8541544B2 (en) | 2013-09-24 |
ES2582208T3 (es) | 2016-09-09 |
JP5960946B2 (ja) | 2016-08-02 |
WO2010050190A1 (fr) | 2010-05-06 |
CN102203290B (zh) | 2015-05-06 |
EP2361988A4 (fr) | 2012-04-04 |
CN104971341B (zh) | 2019-12-13 |
ES2805553T3 (es) | 2021-02-12 |
CN102203290A (zh) | 2011-09-28 |
EP3118326A2 (fr) | 2017-01-18 |
EP3118326A3 (fr) | 2017-05-31 |
JPWO2010050190A1 (ja) | 2012-03-29 |
US20160367628A1 (en) | 2016-12-22 |
US11382952B2 (en) | 2022-07-12 |
EP2361988A1 (fr) | 2011-08-31 |
EP3118326B1 (fr) | 2020-04-29 |
JP2016127820A (ja) | 2016-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212245A1 (en) | Molecular marker for cancer stem cell | |
EP2412825B8 (fr) | Marqueurs de cellules souches leucémiques | |
PT2456889E (pt) | Marcadores para o cancro do endométrio | |
PL2198042T3 (pl) | Nowe markery do wykrywania raka pęcherza moczowego | |
ZA201102362B (en) | Molecular markers in prostate cancer | |
GB0717101D0 (en) | Tumour marker | |
EP2206612A4 (fr) | Pneu pour motocyclette | |
WO2010059686A9 (fr) | Marqueurs pour l'éclampsie | |
GB0811076D0 (en) | Scale track | |
GB0724412D0 (en) | Marker | |
ZA201200888B (en) | New tumor marker | |
GB0714573D0 (en) | Marker gene | |
AU320442S (en) | Marker | |
GB0822155D0 (en) | Marker | |
GB0908071D0 (en) | Marker | |
GB0905964D0 (en) | Marker | |
GB0712776D0 (en) | Information distribution | |
GB0809689D0 (en) | Markers for prostate cancee | |
GB0707671D0 (en) | Fiducial marker | |
GB0718496D0 (en) | Markers | |
HK1163752A1 (en) | Molecular marker for cancer stem cell | |
IL213393A0 (en) | Farmesene synthase | |
GB0724569D0 (en) | Cancer stem cell markers | |
AU2009900489A0 (en) | Marker for polledness | |
GB0701818D0 (en) | Prognostic marker for cancer |